Functional Genetics has developed a portfolio of broad-spectrum antiviral products and discovery technologies. Our product pipeline includes small molecule therapeutics and monoclonal antibodies. Beyond our product development programs, our Random Homozygous Gene Perturbation Technology (RHGP) provides an efficient means to refill our pipeline with novel, validated targets.
FGI-101 - Monoclonal Antibody Targeting TSG101 Functions As A Broad Spectrum Antiviral
FGI-102 - Small Molecule Targeting of TSG101
FGI-103 - Host-Directed Small Molecule With Broad-Spectrum Activity Against Respiratory Viruses
FGI-104 - Small Molecule Inhibitor of Hepatitis C (HCV) and Hepatitis B (HBV) Viruses
FGI-106 - Small Molecule Inhibitor of HIV and Hepatitis C Virus (HCV)